Luminex and Bio-Rad Extend Their Global Sales and Distribution Agreement to 2023
AUSTIN, Texas, April 3, 2012 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has extended its global sales and distribution agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to 2023. In addition, Luminex has granted Bio-Rad global sales and distribution rights for Luminex’s award-winning MAGPIX multiplexing instrument.
As part of the agreement, Bio-Rad will now offer the full range of Luminex’s xMAP® systems including the MAGPIX system, a compact, flexible instrument that simultaneously detects up to 50 different analytes (including proteins and nucleic acids) on a single sample quickly, accurately and reproducibly.
“We are very pleased to extend our sales and distribution agreement and to have Bio-Rad as a global distribution partner for MAGPIX,” said Michael F. Pintek, senior vice president of operations at Luminex. “As a leader in the life science research market, Bio-Rad can provide researchers additional access for this highly innovative instrument that offers a broad range of applications. Together we can accelerate the pace of research and advance healthcare for people around the world.”
“We are looking forward to offering MAGPIX to our customers as part of a complete product offering featuring our analysis software and extensive assay menu,” said Brad Crutchfield, Bio-Rad vice president and group manager Life Science Group. “This partnership with Luminex reflects Bio?Rad’s ongoing commitment to providing the global research community with innovative technologies that will lead to scientific discovery and improved healthcare.”
Providing nearly 5,000 data points in under an hour, MAGPIX was designed to meet the needs of laboratories, academic researchers and scientists who, until now, have not been able to take advantage of the power of multiplexing because of resource and space limitations.
MAGPIX saves vital time in the laboratory, produces faster, accurate, reproducible results and requires less sample input than existing legacy technologies such as ELISA and Western blot. Based on Luminex’s xMAP® Technology, the easy-to-use MAGPIX instrument is compact – comparable in size to a desktop computer – making it an attractive option to a broad array of laboratories and institutions. MAGPIX was awarded a prestigious 2011 Medical Design Excellence Award for Innovative Design and Contribution and recently received CE IVD mark in Europe.
In the United States, MAGPIX is for research use only. Not for use in diagnostic procedures.
For more information on MAGPIX, call 512.219.8020, or visit www.luminexcorp.com/magpix
About Luminex Corporation
Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex’s technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,000 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
Contacts Corporate Contact: Harriss T. Currie, 512.219.8020 Chief Financial Officer and Vice President, Finance firstname.lastname@example.org Luminex Investor Contact: Matthew Scalo, 512.219.8020 Sr. Director Investor Relations email@example.com Luminex Media Contact: Mimi Torrington, 512.219.8020 firstname.lastname@example.org Leslie Denson, 512.241.2233 Porter Novelli Leslie.Denson@porternovelli.com Bio-Rad Media Contact: Tina Cuccia, 510-724-7000 Corporate Communications Manager email@example.com
SOURCE Luminex Corporation